Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04224493 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.
A Phase 3 study of Follicular Lymphoma and Refractory Follicular Lymphoma, sponsored by Epizyme.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 612
- Enrollment target
- 20
- Study locations
NCT04224493 is a Phase 3 study of Follicular Lymphoma and Refractory Follicular Lymphoma that is actively recruiting participants, run by Epizyme. The registered enrollment target is 612 participants, above the 128-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (378% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT04224493, a Phase 3 study of Follicular Lymphoma and Refractory Follicular Lymphoma, is actively recruiting participants, sponsored by Epizyme.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 612 participants
- Enrollment target
- 20
- Study locations
Study Summary
The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to establish a recommended study drug dosage for stage 2 and 3. Stage 1 of the study is completed. Stages 2 and 3 will evaluate and compare how long participants live without their disease getting worse when receiving the study drug in combination with other drug treatment versus the placebo (dummy drug) in combination with other drug treatment.
Conditions Studied
Interventions
- DRUG Placebo oral tablet
- DRUG Tazemetostat
- COMBINATION_PRODUCT Lenalidomide
- COMBINATION_PRODUCT Rituximab
Study Locations (20)
Florida
- Cancer Specialists of North Florida - Fleming Island
- Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center - Fort Myers
- Mayo Clinic - Cancer Clinical Research Office - Jacksonville
- Mayo Clinic - Jacksonville
- Miami Cancer Institute - Miami
- Florida Cancer Affiliates/Ocala Oncology - Clinic - Ocala
- BRCR Medical Center, INC - Plantation
- Florida Cancer Specialists - St. Petersburg
- Florida Cancer Specialists - Panhandle - Tallahassee
- H Lee Moffitt Cancer Center and Research Institute I - Tampa
- Florida Cancer Specialists & Research Institute (FCS) - Atlantis - West Palm Beach
California
- TOI - Clinical Research - Cerritos
- UCSF Fresno - Clovis
- UC San Diego Health Sciences - La Jolla
- UCLA Clinical Research Unit Hematology/Oncology - Santa Monica
Colorado
- Rocky Mountain Cancer Centers (RMCC) - Boulder - Boulder
- St. Mary's Hospital and Regional Medical Center - St. Mary's - Grand Junction
- SCL Health Lutheran Medical Center - Greeley
Alabama
- Southern Cancer Center - Mobile
Arizona
- Arizona Oncology Associates - Tuscon-Rusadill Road - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 612 participants |
| Start Date | 2020-06-11 |
| Est. Completion | 2029-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04224493
The ClinicalTrials.gov registry entry for NCT04224493 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 612 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 128-participant average among 89 other Follicular Lymphoma trials with a reported enrollment target (378% higher). The listed sponsor is Epizyme, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Follicular Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which Placebo oral tablet is the first listed.
NCT04224493 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04224493 about?
NCT04224493 is a clinical study titled "A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.". The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no lo...
What is the current status of trial NCT04224493?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 612 participants. The study started on 2020-06-11. Estimated completion is 2029-03-01.
What conditions does trial NCT04224493 study?
This clinical trial studies the following conditions: Follicular Lymphoma, Refractory Follicular Lymphoma, Relapsed/Refractory Follicular Lymphoma.
What interventions are being tested in trial NCT04224493?
The interventions under investigation include: Placebo oral tablet (DRUG), Tazemetostat (DRUG), Lenalidomide (COMBINATION_PRODUCT), Rituximab (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04224493?
This trial is sponsored by Epizyme, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04224493 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Follicular Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Long-term Extension Study of PCI-32765 (Ibrutinib)
RECRUITING · Phase 3
-
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
RECRUITING · Phase 3
-
A Study of Reduced Dose Radiation Therapy for People With B-Cell Lymphomas
RECRUITING · Phase 3
-
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
ACTIVE NOT RECRUITING · Phase 3
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
COMPLETED · Phase 3
-
A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.